Biologics by McKesson

Overview

Biologics by McKesson is McKesson’s specialty pharmacy arm, focused on oncology, rare disease, and cell / gene therapy launches that need limited-distribution access, specialty handling, patient support, financial navigation, and adjacency to the McKesson commercialization stack. It operated under the Biologics Inc. brand before McKesson’s 2016 acquisition and now sits beside CoverMyMeds, RxTS, RxCrossroads, Ontada, US Oncology, and InspiroGene inside the McKesson portfolio.

Biologics is not a PBM-owned specialty pharmacy and not a high-volume retail-specialty operator. It is launch-grade specialty pharmacy: more focused than the largest PBM-owned SPs, more enterprise-supported than rare-disease-only specialists, and a frequent exclusive or limited distribution choice on oncology and rare-disease approvals.

Specialty Pharmacy Capability Model

The framework below standardizes how Rx Almanac evaluates specialty-pharmacies capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Biologics by McKesson is evaluated as Launch-grade oncology, rare-disease, and cell / gene specialty pharmacy backed by McKesson distribution and manufacturer-services infrastructure.

Capability	Buyer should compare	Biologics by McKesson readout
Specialty dispensing and channel access	Licensed dispensing footprint, payer network access, LDD participation, referral capture, and ability to serve the target patient geography.	Major fulfillment handoff. Biologics is repeatedly selected for oncology, rare-disease, limited-distribution, and exclusive specialty pharmacy programs.
Benefits, PA, and reimbursement support	Benefit investigation, PA support, appeals coordination, copay/PAP routing, and reimbursement troubleshooting at the pharmacy edge.	Hub-adjacent. Public materials show program-specific hub / PAP responsibilities for selected launches; buyers should define the exact BI / PA and hub handoff model in the RFP.
Clinical therapy management and adherence	Pharmacist counseling, disease-specific protocols, refill outreach, injection training, persistence programs, and clinical escalation.	Engagement model. Public materials emphasize pharmacists with therapy knowledge, experienced nurses, and financial counselors familiar with assistance programs.
Cold chain, REMS, and complex handling	Temperature control, REMS certification, hazardous/controlled-substance handling, biologics, CGT, and other special distribution requirements.	Product-specific. Biologics belongs in diligence for REMS, CGT, oncology, and rare-disease products, but each product’s service line needs explicit validation.
Manufacturer data and outcomes reporting	Status feeds, dispense data, adherence/outcomes reporting, inventory visibility, and reporting cadence suitable for launch governance.	Contract-sensitive. Buyers should specify data fields, cadence, abandonment definitions, and reconciliation rights rather than assuming reporting depth from the McKesson parent stack.
Site-of-care, infusion, or health-system coordination	Home infusion, ambulatory infusion, provider-office coordination, health-system capture, and buy-and-bill support where relevant.	Adjacent. Evaluate Biologics together with McKesson distribution, CoverMyMeds / RxTS, RxCrossroads, Ontada, US Oncology, and InspiroGene when the pathway crosses pharmacy, hub, and provider operations.

Buyer Fit

• Use-case fit: Oncology, rare-disease, ultra-rare, and advanced-therapy launches where exclusive or limited specialty pharmacy selection is commercially material and the brand can use McKesson distribution, CoverMyMeds / RxTS, RxCrossroads, Ontada, US Oncology, and InspiroGene adjacency.
• Best-fit buyers: Oncology and rare-disease manufacturers needing a single SP partner that pairs high-touch pharmacist / nurse / financial-counselor support with McKesson enterprise reach, including 2025-2026 Menkes disease, acromegaly, ITP, NSCLC, and PROS launches.
• Less ideal fit: Programs that depend mainly on PBM-owned routing power, formulary adjacency, or captive payer / claims data; PBM-owned SPs are the comparison set there.
• Commercial fit: Pricing is undisclosed; expect an RFP-led scope with SLAs across BI / PA, dispensing, hub responsibilities where in scope, REMS, cold chain, and manufacturer reporting.
• Profile signal: Repeated public limited and exclusive SP roles across oncology, rare disease, and complex therapies in 2025-2026, plus a hub-adjacent Pharmacy Elite engagement for Rigel’s Tavalisse, Gavreto, and Rezlidhia.
• Governance diligence: Confirm that public therapy-list inclusion is being matched by actual payer access and LDD eligibility for the specific product, and that handoff governance across hub, specialty pharmacy, data, distribution, and oncology provider infrastructure is explicit in the SOW.

Differentiators

• Launch-grade specialty pharmacy focus: Biologics is strongest when product complexity makes specialty pharmacy selection commercially material.
• Oncology and rare-disease credibility: Public materials repeatedly position Biologics around oncology, rare disease, and complex specialty therapies.
• Hub-adjacent role: Program-specific materials show Biologics can support more than dispensing when the launch requires hub services, PAP dispensing, or coordinated patient support.
• McKesson stack adjacency: Buyers can evaluate Biologics alongside McKesson distribution, CoverMyMeds / RxTS access workflows, RxCrossroads, Ontada, US Oncology, and InspiroGene.
• High-touch care model: Pharmacists, nurses, and financial counselors are a clearer differentiator here than retail footprint or broad PBM channel power.

RFP Questions

• Which option is Biologics proposed as the exclusive specialty pharmacy, one limited-network pharmacy, a backup pharmacy, a hub services provider, a PAP dispensing pharmacy, or some combination?
• Which payer networks, LDD relationships, REMS requirements, state licenses, cold-chain workflows, and disease-specific protocols apply to this product?
• Which McKesson assets are in scope: Biologics, CoverMyMeds, RxCrossroads, RxTS, Ontada, US Oncology, InspiroGene, 3PL, or core distribution?
• What are the operational handoffs between enrollment, BI, PA, denial conversion, affordability, PAP, dispensing, adherence, and reporting?
• What metrics are guaranteed: time to first fill, PA approval / denial, abandonment, average patient OOP, refill persistence, adherence, patient satisfaction, and prescriber satisfaction?
• What reporting fields, cadence, source systems, suppression thresholds, and reconciliation rights will the manufacturer receive?
• How will Biologics perform against PBM-owned specialty pharmacies when payer access, formulary adjacency, or captive claims data matter?

Recent Activity

• Jan 2026 - Biologics became the exclusive U.S. specialty pharmacy, hub services provider, and PAP dispensing pharmacy for ZYCUBO, the first FDA-approved treatment for Menkes disease.
• Jan 2026 - Biologics’ Pharmacy Elite offering was selected as the hub for Rigel’s Tavalisse, Gavreto, and Rezlidhia programs.
• Sep 2025 - Biologics was selected as a limited specialty pharmacy provider for PALSONIFY and WAYRILZ.
• Aug 2025 - PIQRAY and VIJOICE became available exclusively through Biologics by McKesson.
• Jun 2025 - Biologics was selected as a limited specialty pharmacy provider for IBTROZI.